AMLs with TET2 or IDH mutation, and IDH mutated gliomas have more pronounced hypermethylation profiles than their non-mutated counterparts and share overlapping epigenetic signatures (Figueroa et al., 2010; Xu et al., 2011). This evidence concerns the gene IDH2 and central nervous system cancer.